Table 1.
Baseline characteristics and outcomes of the PLWH who contributed follow-up periods in unvaccinated and vaccinated groups.
| Variable | Unvaccinated group (n = 3128)a | Partially-vaccinated group (n = 2476) | Fully-vaccinated group (n = 236) | P value |
|---|---|---|---|---|
| Age, median (IQR), years | 41 (35–50) | 41 (35–50) | 41 (34–50) | 0.470 |
| Male sex, n (%) | 3121 (99.8) | 2472 (99.8) | 236 (100) | 0.688 |
| Receiving cART, n (%) | 3126 (99.9) | 2474 (99.9) | 236 (100) | 0.893 |
| INSTI and NRTIs | 2906 (92.9) | 2300 (92.9) | 217 (91.9) | 0.857 |
| Boosted PI and NRTIs | 13 (0.4) | 11 (0.4) | 0 (0) | 0.594 |
| NNRTI and NRTIs | 197 (6.3) | 155 (6.3) | 19 (8.1) | 0.550 |
| Boosted PI and INSTI | 10 (0.3) | 8 (0.3) | 0 (0) | 0.684 |
| Baseline CD4 count, median (IQR), cells/mm3 | 625 (467–809) | 635 (478–825) | 587 (463–779) | 0.163 |
| Baseline PVL, median (range), log10 copies/mL | UD (UD-6.23) | UD (UD-6.23) | UD (UD-5.77) | 0.841 |
| PVL <20 copies/mL, n (%) | 2592 (82.9) | 2080 (84.0) | 205 (86.9) | 0.195 |
| Types of vaccine, n (%) | ||||
| ChAdOx1 nCoV-19 | NA | 1744 (70.4) | 169 (71.6) | 0.712 |
| mRNA-1273 | NA | 592 (23.9) | 36 (15.3) | 0.003 |
| MVC-COV1901 | NA | 110 (4.4) | 4 (1.7) | 0.044 |
| BNT162b2 | NA | 11 (0.4) | 10 (4.2) | <0.001 |
| Othersb | NA | 18 (0.7) | 17 (7.2) | <0.001 |
| Vaccination period, n (%)c | <0.001 | |||
| March–April, 2021 | NA | 37 (1.5) | 8 (3.4) | |
| May–July, 2021 | NA | 2029 (81.9) | 119 (50.4) | |
| August–September, 2021 | NA | 410 (16.6) | 109 (46.2) | |
| Confirmed cases of SARS-CoV-2 infection, n (%) | 33 (1.1) | 4 (0.2) | 0 (0) | <0.001 |
| Follow-up duration, PDFU | 516,892 | 139,163 | 12,011 | – |
| Incidence rates of SARS-CoV-2 infection, cases per 100,000 PDFU | 6.4 | 2.9 | 0 | – |
Abbreviations: CART, combination antiretroviral therapy; INSTI, integrase strand transfer inhibitor; IQR, interquartile range; NA, not available; NRTI, nucleoside reverse-transcriptase inhibitor; NNRTI, non-nucleoside reverse-transcriptase inhibitor; PDFU, person-days of follow-up; PI, protease inhibitor; PLWH, people living with HIV; PVL, plasma HIV RNA load; UD, undetectable.
Three participants had received COVID-19 vaccination at least 14 days before 1 March, 2021, for which they did not contribute follow-up periods in the unvaccinated group.
Participants received Sinovac and Sinopharm COVID-19 vaccines in China.
The date on which participants received the first dose of vaccination for the partially-vaccinated group, or the second dose of vaccination for the fully-vaccinated group.